CSF3 and acute myeloid leukemia: Ruan et al. published a retrospective analysis of children who received CLAG-M (cladribine, cytarabine, granulocyte colony-stimulating factor [G-CSF], and mitoxantrone) compared to MEC/IEC (mitoxantrone, etoposide, and cytarabine, or idarubicin, etoposide, and cytarabine) in pediatric patients (aged 1–15 years) with relapsed/refractory AML [27].